Dr. Michael Lee Aksamit, R.P. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 9411 Chestnut Dr, Bennington, NE 68007 Phone: 402-657-1793 Fax: 402-939-0041 |
News Archive
Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012.
A research team led by St. Jude Children's Research Hospital scientists has discovered details of how the abnormal breakage and rearrangement of chromosomes in white blood cells triggers a particularly aggressive form of acute lymphoblastic leukemia (ALL). Such leukemias are cancers of white blood cells, in which genetic mutations trigger overproduction of immature cells, called lymphoblasts.
For patients with head and neck cancer, accurately determining how advanced the cancer is and detecting secondary cancers usually means undergoing numerous tests - until now.
Misonix, Inc., a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has entered into a new, three year distribution agreement with Xenith, LLC, based in Dubai, UAE, for the distribution of the SonaStar(TM) Ultrasonic Surgical Aspirator, the BoneScalpel(TM) Ultrasonic Bone Cutter, and the SonicOne® Ultrasonic Wound Debrider.
By combining a conventional laboratory measurement of blood clotting time (known as the International Normalized Ratio or INR) with a new test of blood clot strength, based upon thrombelastography (TEG), researchers at the University of Colorado's Department of Surgery, Denver, are able to quickly and efficiently assess the overall ability of blood to clot and identify trauma patients who were most in need of a massive blood transfusion.
› Verified 2 days ago